EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience

Bart Hendrikx, Eline-Alice Brys iD, Alexandra Dili, Thomas Apers, Vera Hartman iD, Martin Brichard iD, Filip Gryspeerdt, Claude Bertrand iD, Geert Roeyen, Frederik Berrevoet iD

Current Oncology · 2025

DOI: 10.3390/curroncol32100574 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, 2025. Verfasst von Bart Hendrikx und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Gent, Belgium. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Electroporation, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of 10%. Irreversible electroporation (IRE), a non-thermal ablative technique, may improve outcomes in locally advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). This multi-center retrospective study aims to evaluate postoperative complications, 90-day mortality, and survival following IRE.

Methods

35 pancreatic cancer patients were treated with IRE between 2015 and 2023 across three Belgian hospitals. IRE was performed for tumor destruction in unresectable LAPC (n = 13) (IRE-LAPC) and for margin accentuation during resection in BRPC (n = 22) (IRE-MA). Primary endpoints were 90-day mortality, complications, and survival (only 33 patients included); secondary endpoints included metastases, local recurrence, and R0-resection rates.

Results

Postoperative complications occurred in 23.1% (IRE-LAPC) and 68.2% (IRE-MA) of patients. Overall survival at 24 months was 27.3% (IRE-LAPC) and 27.3% (IRE-MA). Median survival time was 12.7 months (IRE-LAPC) and 13.3 months (IRE-MA). Six patients (17.1%) died within 90 days. Metastasis occurred in 51.5% of patients after a median time of 9.8 months. Local recurrence was seen in 24.2% of patients after a median time of 7.5 months. R0 resection was achieved in 63.6% (IRE-MA).

Discussion

IRE for margin accentuation in BRPC is associated with relatively high morbidity and mortality rates and cannot be considered beneficial. In unresectable LAPC, IRE appears relatively safe for local disease control. Further research should clarify patient selection and optimize its therapeutic role.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalElectroporationPancreatic NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

irreversible electroporationmargin accentuationoutcomespancreatic cancertumor ablation

Autor:innen und Institutionen

  • Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Gent, Belgium.
  • Department of Hepatobiliary, Transplant and Endocrine Surgery, Antwerp University Hospital, 2650 Edegem, Belgium.
  • Faculty of Medicine and Health Sciences, Ghent University, 9000 Gent, Belgium.
  • Department of Digestive, Endocrine and General Surgery, CHU-UCL Namur, Site of Mont Godinne, 5530 Namur, Belgium.
  • Department of Surgery, ZAS Hospital, 2030 Antwerp, Belgium.

ORCID-Profile: Eline-Alice Brys, Vera Hartman, Martin Brichard, Claude Bertrand, Frederik Berrevoet

Zitieren

APA

Hendrikx, B., Brys, E. A., Dili, A., Apers, T., Hartman, V., Brichard, M., Gryspeerdt, F., Bertrand, C., Roeyen, G., & Berrevoet, F. (2025). Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience. Current Oncology. https://doi.org/10.3390/curroncol32100574

Vancouver

Hendrikx B, Brys EA, Dili A, Apers T, Hartman V, Brichard M, et al. Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience. Current Oncology. 2025. doi:10.3390/curroncol32100574

BibTeX
@article{Hendrikx2025,
  author = {Hendrikx, Bart and Brys, Eline-Alice and Dili, Alexandra and Apers, Thomas and Hartman, Vera and Brichard, Martin and Gryspeerdt, Filip and Bertrand, Claude and Roeyen, Geert and Berrevoet, Frederik},
  title = {Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32100574}
}
Kostenlos starten →